四重暴露/难治性多发性骨髓瘤:既往接受过抗 CD38、IMiDs、蛋白酶体抑制剂与 BCMA 靶向治疗的患者 Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies. PubMed 2026/05/06 发表Clin Lymphoma Myeloma LeukQ1 · IF 4.1(JCR 2025) 靶点:CD38靶点:BCMA多发性骨髓瘤淋巴瘤白血病地区:欧洲
SOHO 最新进展与后续问题 | 骨髓瘤早期复发的治疗:非 CAR-T 细胞 SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell. PubMed 2025/10/04 发表Clin Lymphoma Myeloma LeukQ1 · IF 4.1(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤淋巴瘤白血病
拓宽视野:CAR-T 细胞在当前适应证之外的潜在应用 Broadening the horizon: potential applications of CAR-T cells beyond current indications. PubMed 2023/11/27 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:CD30靶点:CD38靶点:BCMA技术:CAR-T弥漫大B细胞淋巴瘤急性淋巴细胞白血病慢性淋巴细胞白血病
后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理:欧洲骨髓瘤网络(EMN)共识文件 Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). PubMed 2023/05/04 发表LeukemiaQ1 · IF 8.8(JCR 2025) 靶点:CD38靶点:BCMA多发性骨髓瘤白血病地区:欧洲
CAR 与嵌合共刺激受体联用增强 T 细胞对低抗原密度的敏感性并促进持久性 Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. PubMed 2021/12/08 发表Sci Transl MedQ1 · IF 15.6(JCR 2025) 靶点:CD19靶点:CD38靶点:BCMA技术:CAR-T急性淋巴细胞白血病多发性骨髓瘤